134 related articles for article (PubMed ID: 31544815)
1. Impact of Acetylated and Non-Acetylated Fucose Analogues on IgG Glycosylation.
Zimmermann M; Ehret J; Kolmar H; Zimmer A
Antibodies (Basel); 2019 Jan; 8(1):. PubMed ID: 31544815
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.
Mishra N; Spearman M; Donald L; Perreault H; Butler M
J Biotechnol; 2020; 324S():100015. PubMed ID: 34154738
[TBL] [Abstract][Full Text] [Related]
3. Use of 5-Thio-L-Fucose to modulate binding affinity of therapeutic proteins.
Zimmermann M; Nguyen M; Schultheiss CM; Kolmar H; Zimmer A
Biotechnol Bioeng; 2021 May; 118(5):1818-1831. PubMed ID: 33501689
[TBL] [Abstract][Full Text] [Related]
4. Development of orally active inhibitors of protein and cellular fucosylation.
Okeley NM; Alley SC; Anderson ME; Boursalian TE; Burke PJ; Emmerton KM; Jeffrey SC; Klussman K; Law CL; Sussman D; Toki BE; Westendorf L; Zeng W; Zhang X; Benjamin DR; Senter PD
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5404-9. PubMed ID: 23493549
[TBL] [Abstract][Full Text] [Related]
5. Applying Acylated Fucose Analogues to Metabolic Glycoengineering.
Rosenlöcher J; Böhrsch V; Sacharjat M; Blanchard V; Giese C; Sandig V; Hackenberger CPR; Hinderlich S
Bioengineering (Basel); 2015 Nov; 2(4):213-234. PubMed ID: 28952479
[TBL] [Abstract][Full Text] [Related]
6. Cellular Fucosylation Inhibitors Based on Fluorinated Fucose-1-phosphates*.
Pijnenborg JFA; Visser EA; Noga M; Rossing E; Veizaj R; Lefeber DJ; Büll C; Boltje TJ
Chemistry; 2021 Feb; 27(12):4022-4027. PubMed ID: 33336886
[TBL] [Abstract][Full Text] [Related]
7. Facile Modulation of Antibody Fucosylation with Small Molecule Fucostatin Inhibitors and Cocrystal Structure with GDP-Mannose 4,6-Dehydratase.
Allen JG; Mujacic M; Frohn MJ; Pickrell AJ; Kodama P; Bagal D; San Miguel T; Sickmier EA; Osgood S; Swietlow A; Li V; Jordan JB; Kim KW; Rousseau AC; Kim YJ; Caille S; Achmatowicz M; Thiel O; Fotsch CH; Reddy P; McCarter JD
ACS Chem Biol; 2016 Oct; 11(10):2734-2743. PubMed ID: 27434622
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation.
Zhou Y; Fukuda T; Hang Q; Hou S; Isaji T; Kameyama A; Gu J
Sci Rep; 2017 Sep; 7(1):11563. PubMed ID: 28912543
[TBL] [Abstract][Full Text] [Related]
9. Identifying the differences in mechanisms of mycophenolic acid controlling fucose content of glycoproteins expressed in different CHO cell lines.
Zhang A; Tsang VL; Markely LR; Kurt L; Huang YM; Prajapati S; Kshirsagar R
Biotechnol Bioeng; 2016 Nov; 113(11):2367-76. PubMed ID: 27093551
[TBL] [Abstract][Full Text] [Related]
10. L-fucose, a sugary regulator of antitumor immunity and immunotherapies.
Adhikari E; Liu Q; Burton C; Mockabee-Macias A; Lester DK; Lau E
Mol Carcinog; 2022 May; 61(5):439-453. PubMed ID: 35107186
[TBL] [Abstract][Full Text] [Related]
11. A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.
Roy G; Martin T; Barnes A; Wang J; Jimenez RB; Rice M; Li L; Feng H; Zhang S; Chaerkady R; Wu H; Marelli M; Hatton D; Zhu J; Bowen MA
MAbs; 2018 Apr; 10(3):416-430. PubMed ID: 29400603
[TBL] [Abstract][Full Text] [Related]
12. Core fucosylation of N-linked glycans in leukocyte adhesion deficiency/congenital disorder of glycosylation IIc fibroblasts.
Sturla L; Fruscione F; Noda K; Miyoshi E; Taniguchi N; Contini P; Tonetti M
Glycobiology; 2005 Oct; 15(10):924-34. PubMed ID: 15917429
[TBL] [Abstract][Full Text] [Related]
13. Comparative core fucosylation analysis of some major therapeutic antibody N-glycans by direct infusion ESI-MS and CE-LIF detection.
Wang Y; Santos M; Guttman A
J Sep Sci; 2013 Sep; 36(17):2862-7. PubMed ID: 23801428
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers.
Disis ML; Corulli LR; Gad EA; Koehnlein MR; Cecil DL; Senter PD; Gardai SJ; Okeley NM
Mol Cancer Ther; 2020 May; 19(5):1102-1109. PubMed ID: 32165557
[TBL] [Abstract][Full Text] [Related]
15. Strategies for controlling afucosylation in monoclonal antibodies during upstream manufacturing.
Rish AJ; Siddiquee K; Huang Z; Xu J; Anderson CA; Borys MC; Khetan A
Biotechnol J; 2023 Jul; 18(7):e2200604. PubMed ID: 37029472
[TBL] [Abstract][Full Text] [Related]
16. Assignment of Core versus Antenna Fucosylation Types in Protein N-Glycosylation via Procainamide Labeling and Tandem Mass Spectrometry.
Nwosu C; Yau HK; Becht S
Anal Chem; 2015 Jun; 87(12):5905-13. PubMed ID: 25978524
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.
Kanda Y; Imai-Nishiya H; Kuni-Kamochi R; Mori K; Inoue M; Kitajima-Miyama K; Okazaki A; Iida S; Shitara K; Satoh M
J Biotechnol; 2007 Jun; 130(3):300-10. PubMed ID: 17559959
[TBL] [Abstract][Full Text] [Related]
18. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.
von Horsten HH; Ogorek C; Blanchard V; Demmler C; Giese C; Winkler K; Kaup M; Berger M; Jordan I; Sandig V
Glycobiology; 2010 Dec; 20(12):1607-18. PubMed ID: 20639190
[TBL] [Abstract][Full Text] [Related]
19. Cephalostatin analogues--synthesis and biological activity.
Flessner T; Jautelat R; Scholz U; Winterfeldt E
Fortschr Chem Org Naturst; 2004; 87():1-80. PubMed ID: 15079895
[TBL] [Abstract][Full Text] [Related]
20. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.
Nechansky A; Schuster M; Jost W; Siegl P; Wiederkum S; Gorr G; Kircheis R
Mol Immunol; 2007 Mar; 44(7):1815-7. PubMed ID: 17011625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
